Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

Mads Emil Bjørn, Marie Klinge Brimnes, Sif Gudbrandsdottir, Christen Lykkegaard Andersen, Henrik Enghusen Poulsen, Trine Henriksen, Hans Carl Hasselbalch, Claus Henrik Nielsen
  • Leukemia & Lymphoma, February 2019, Taylor & Francis
  • DOI: 10.1080/10428194.2019.1579323

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Mr Mads E Bjørn